drugset / Trial / NCT06603077

A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

NCT06603077 ↗

Phase 2 Completed 253 enrolled Avalo Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to evaluate the efficacy and safety of AVTX-009 compared with placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).

Timeline

Start
2024-09-16
Primary completion
2026-02-23
Completion
2026-03-17

Drugs

EvaluationDrugModalityDoseRoute
Subject AVTX-009 Unknown — Subcutaneous